Virtual screening of combinatorial library of novel benzenesulfonamides on mycobacterial carbonic anhydrase II

Dikant, F.; Gáplovský, F.; Garaj, V.

doi:10.1515/afpuc-2016-0020

Abstract

Combinatorial library of novel benzenesulfonamides was docked (Schrodinger Glide) into mycobacterial carbonic anhydrase (mtCA II) and human (hCA II) isoforms with an aim to find drug candidates with selective activity on mtCA II. The predicted selectivity was calculated based on optimized MM-GBSA free energies for ligand enzyme interactions. Selectivity, LogP (o/w) and interaction energy were used to calculate the selection index which determined the subset of best scoring molecules selected for further evaluation. Structure-activity relationship was found for fragment subsets, showing us the possible way regarding how to influence lipophilicity without affecting ligand-enzyme binding properties.

References

[1] Behnke CA, Le Trong I, Godden JW, et al. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr. 2010;66:616-627.10.1107/S0907444910006554
Search in Google Scholar Back to article
[2] Ceruso M, Vullo D, Scozzafava A, Supuran CT. Inhibition of human carbonic anhydrase isoforms I-XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties. Bioorg Med Chem. 2013;21:6929-6936.10.1016/j.bmc.2013.09.031
Search in Google Scholar Back to article
[3] Covarrubias AS, Bergfors T, Jones TA, Hogbom M. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem. 2006;281:4993-4999.10.1074/jbc.M510756200
Search in Google Scholar Back to article
[4] Covarubias AS, Larsson AM, Hogbom M, et al. Structure and Function of Carbonic Anhydrases from Mycobacterium tuberculosis. J Biol Chem. 2005;280:18782-18789.10.1074/jbc.M414348200
Search in Google Scholar Back to article
[5] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. J Med Chem. 2006;49:6177-6196.10.1021/jm051256o
Search in Google Scholar Back to article
[6] Keckesova S, Sedlarova E, Cizmarik J, et al. Antimycobacterial activity of novel derivatives of arylcarbonyloxyaminopro-panols. Ceska Slov Farm. 2009;58:203-207.
Search in Google Scholar Back to article
[7] Li J, Abel R, Zhu K, et al. The VSGB 2.0 Model: A Next Generation Energy Model for High Resolution Protein Structure Modelling. Proteins 2011;79:2794-2812.10.1002/prot.23106
Search in Google Scholar Back to article
[8] Lipinski C, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.10.1016/S0169-409X(00)00129-0
Search in Google Scholar Back to article
[9] Maresca A. Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with. Bioorg Med Chem Lett. 2009;19:4929-4932.10.1016/j.bmcl.2009.07.088
Search in Google Scholar Back to article
[10] Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A. 2003;100:12989-12994.10.1073/pnas.2134250100
Search in Google Scholar Back to article
[11] Shelley JC, Cholleti A, Frye L, Greenwood JR, Timlin MR, Uchimaya M. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J Comp-Aided Mo. Design. 2007;21:681-691.
Search in Google Scholar Back to article
[12] Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb). 2008;88(1 suppl):s3- s17.10.1016/S1472-9792(08)70032-5
Search in Google Scholar Back to article
[13] Supuran CT. Carbonic anhydrases - An overview. Curr Pharm Des. 2008;14:603-614.10.2174/13816120878387788418336305
Search in Google Scholar Back to article
[14] Supuran CT. Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets. Curr Pharm Des. 2010;16:3233-3245.10.2174/13816121079342979720819070
Search in Google Scholar Back to article
[15] Upadhayaya RS, Kulkarni GM, Vasireddy NR, Vandavasi JK, Dixit SS, Sharma V, Chattopadhyaya J. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg Med Chem 2009;17:4681-4692.10.1016/j.bmc.2009.04.06919457676
Search in Google Scholar Back to article
[16] Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615-2623.10.1021/jm020017n12036371
Search in Google Scholar Back to article
[17] Waisser K, Dolezal R, Palat K, Cizmarik J, Kaustova J. QSAR study of antimycobacterial activity of quaternary ammonium salts of piperidinylethyl esters of alkoxysubstituted phenylcarbamic acids. Folia Microbiologica. 2006;51:21-24.10.1007/BF0293144416821706
Search in Google Scholar Back to article
[18] WHO. WHO Global tuberculosis report. WHO; 2013.
Search in Google Scholar Back to article

Virtual screening of combinatorial library of novel benzenesulfonamides on mycobacterial carbonic anhydrase II

Abstract

Paradigm

My account